Aquestive Therapeutics, Inc. Forecast, price target & analysts
Aquestive Therapeutics, Inc. Target price 2025 - Analyst rating & recommendation
Aquestive Therapeutics, Inc. Classifications & Recommendation:
Aquestive Therapeutics, Inc. Price Target
| Target Price | $9.86 |
| Price | $3.04 |
| Potential |
224.38%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Aquestive Therapeutics, Inc. 2026 .
The average Aquestive Therapeutics, Inc. target price is $9.86.
This is
224.38%
register free of charge
$15.00
393.42%
register free of charge
$4.75
56.25%
register free of charge
|
|
| A rating was issued by 9 analysts: 9 Analysts recommend Aquestive Therapeutics, Inc. to buy, 0 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Aquestive Therapeutics, Inc. stock has an average upside potential 2026 of
224.38%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 57.56 | 49.60 |
| 13.80% | 13.83% | |
| EBITDA Margin | -52.21% | -100.69% |
| 95.02% | 92.87% | |
| Net Margin | -80.99% | -127.16% |
| 244.73% | 57.00% |
9 Analysts have issued a sales forecast Aquestive Therapeutics, Inc. 2025 . The average Aquestive Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Aquestive Therapeutics, Inc. EBITDA forecast 2025. The average Aquestive Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
1 Analyst has issued a net profit forecast Aquestive Therapeutics, Inc. 2025 . The average Aquestive Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.51 | -0.69 |
| 292.31% | 35.29% | |
| P/E | negative | |
| EV/Sales | 7.08 |
1 Analysts have issued a Aquestive Therapeutics, Inc. forecast for earnings per share. The average Aquestive Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Aquestive Therapeutics, Inc....
Current Aquestive Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 02 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 10 2025 |
| Lake Street |
Locked
➜
Locked
|
Locked | Mar 07 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 20 2024 |
| Cantor Fitzgerald |
Locked
➜
Locked
|
Locked | Dec 17 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 11 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 06 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 02 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 10 2025 |
|
Locked
Lake Street:
Locked
➜
Locked
|
Mar 07 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 20 2024 |
|
Locked
Cantor Fitzgerald:
Locked
➜
Locked
|
Dec 17 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 11 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 06 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
